CNS Pharmaceuticals (CNSP) Expected to Announce Earnings on Wednesday

CNS Pharmaceuticals (NASDAQ:CNSP) will likely be announcing its results before the market opens on Wednesday, February 25th. Analysts expect the company to announce earnings of ($5.09) per share for the quarter.

CNS Pharmaceuticals Stock Performance

Shares of CNSP opened at $3.21 on Monday. The firm’s 50 day moving average price is $5.53 and its two-hundred day moving average price is $6.79. CNS Pharmaceuticals has a twelve month low of $3.09 and a twelve month high of $55.20. The firm has a market cap of $1.99 million, a P/E ratio of -0.10 and a beta of 2.70.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in the business. Armistice Capital LLC bought a new stake in CNS Pharmaceuticals during the 2nd quarter worth about $335,000. Ikarian Capital LLC bought a new position in shares of CNS Pharmaceuticals in the 4th quarter valued at about $241,000. Finally, Boothbay Fund Management LLC bought a new position in shares of CNS Pharmaceuticals in the 4th quarter valued at about $71,000. Institutional investors own 14.02% of the company’s stock.

Analysts Set New Price Targets

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of CNS Pharmaceuticals in a research note on Wednesday, January 21st. Two investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to MarketBeat, the company presently has a consensus rating of “Hold” and an average price target of $20.00.

CNS Pharmaceuticals Company Profile

CNS Pharmaceuticals, Inc, headquartered in Houston, Texas, is a clinical-stage biopharmaceutical company focused on developing therapies for aggressive central nervous system tumors. The company’s lead candidate, berubicin, is an anthracycline derivative engineered to cross the blood-brain barrier for the treatment of glioblastoma multiforme and other brain cancers. In addition to berubicin, CNS Pharmaceuticals is advancing WP1066, an immunotherapy agent designed to inhibit the STAT3 signaling pathway and enhance anti-tumor immune activity in the tumor microenvironment.

Berubicin has completed a Phase 1 clinical trial in patients with recurrent glioblastoma, where it demonstrated proof-of-concept signals, and is currently in Phase 2 development.